19
total announcements
539524.BO · 15 min delayed
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has published a notice to Equity Shareholders regarding unclaimed Equity Shares (Interim Dividend FY 2019-20), due for transfer to Investor Education and Protection Fund (IEPF) pursuant to Section 124(6) of the Companies Act, 2013.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has completed the subscription of a 30% stake in Neuome Technologies Private Limited, making Neuome an associate of the company.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has incorporated a step-down subsidiary company, Dr Lal PathLabs Indomed LLC, in Tashkent, Uzbekistan, with its wholly-owned subsidiary Dr Lal PathLabs FZCO, Dubai, United Arab Emirates, subscribing to 70% of its share capital.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has informed the exchange about the allotment of 2,11,050 equity shares under its Employee Stock Option Plan 2022, increasing its paid-up equity share capital to INR 1,67,84,88,200 divided into 16,78,48,820 equity shares of INR 10/- each.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has announced its Q1 FY27 earnings conference call transcript, with a revenue of Rs. 798 crore, registering a year-on-year growth of 19.1%. The company has launched 116 new tests, including 4 first-in-India tests, and has expanded its advanced diagnostics capabilities.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has informed the exchange that Mr. Gurinder Singh Kalra has completed his tenure as an Independent Director of the Company on July 26, 2026, and ceases to be an Independent Director with effect from the same date.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has announced the voting results of its 32nd Annual General Meeting (AGM), with the Scrutinizer's Report confirming the passing of all resolutions, including the adoption of audited financial statements for the financial year ended March 31, 2026.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd held its 32nd Annual General Meeting (AGM) on July 25, 2026, through video conference. The meeting approved the audited standalone financial statements for the financial year ended March 31, 2026, and declared a final dividend of INR 4 per equity share. The company also revised the remuneration structure of its Executive Chairman and Whole-Time Director, (Hony) Brig Dr Arvind Lal, and Whole-Time Director, Dr Vandana Lal. Additionally, the meeting re-appointed (Hony) Brig Dr Arvind Lal as Executive Chairman and Whole-Time Director for a period of five consecutive years.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has published its financial results for the quarter ended June 30, 2026, in accordance with Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has announced the availability of the audio recording of its earnings conference call with investors/analysts for Q1 FY27 on its website.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has announced its Q1 FY27 financial results, with revenue increasing by 19.1% to Rs 798 Cr, EBITDA increasing by 28.7% to Rs 247 Cr, and PAT increasing by 27.2% to Rs 170 Cr. The company has also declared an interim dividend of 50% and has made two acquisitions in Ghana and India.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has announced its un-audited financial results for the quarter ended June 30, 2026, and will be sharing an earnings presentation with analysts and investors.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has announced its un-audited financial results for the quarter ended June 30, 2026, and has approved an interim dividend of INR 5 per equity share. The company has also approved the granting of stock options under its Employee Restricted Stock Unit Plan 2025 to eligible employees, and has taken note of the acquisition of stakes in Sunshine Healthcare Limited and Neuome Technologies Private Limited by its subsidiaries.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has announced its un-audited financial results for the quarter ended June 30, 2026, along with the declaration of an interim dividend of INR 5 per equity share. The company has also approved the acquisition of stakes in Sunshine Healthcare Limited and Neuome Technologies Private Limited through its subsidiaries.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has announced its un-audited financial results for the quarter ended June 30, 2026, and approved the declaration of an interim dividend of INR 5 per equity share. The company has also granted stock options to eligible employees and approved the acquisition of stakes in Sunshine Healthcare Limited and Neuome Technologies Private Limited.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has announced its un-audited financial results for the quarter ended June 30, 2026, and has approved the declaration of an interim dividend of INR 5 per equity share. The company has also approved the granting of stock options to eligible employees and has taken note of the acquisition of stakes in Sunshine Healthcare Limited and Neuome Technologies Private Limited by its subsidiaries.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has announced its un-audited financial results for the quarter ended June 30, 2026, and declared an interim dividend of INR 5 per equity share. The company has also approved the acquisition of stakes in Sunshine Healthcare Limited and Neuome Technologies Private Limited through its subsidiaries.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has announced its un-audited financial results for the quarter ended June 30, 2026, and has approved the declaration of an interim dividend of INR 5 per equity share. The company has also approved the granting of stock options under its Employee Restricted Stock Unit Plan 2025 to eligible employees. Additionally, the company's Board of Directors has taken note of the acquisition of stakes in Sunshine Healthcare Limited and Neuome Technologies Private Limited by its subsidiaries.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has announced its un-audited financial results for the quarter ended June 30, 2026, with the Board of Directors approving the same. The company has also declared an interim dividend of INR 5 per equity share, and has granted stock options to eligible employees. Additionally, the company's wholly owned subsidiaries have approved the acquisition of stakes in Sunshine Healthcare Limited and Neuome Technologies Private Limited.